Concepedia

Author

Lenushka Maharaj

Queen Mary University of London

Also Known As

Lenushka Maharaj

21

Publications

1K

Citations

8

H-Index

17

Concepts

All Affiliations

Queen Mary University of LondonMillennium Engineering and Integration (United States)University of AucklandThe University of Western AustraliaSt Bartholomew's Hospital
LM

About

Lenushka Maharaj is an author at Queen Mary University of London specializing in medicine, pharmacology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

570

2

Biochemistry

2

2

421

3

Cell Biology

2

2

149

4

Natural Sciences

1

1

242

5

Immunology

1

1

37

Lenushka Maharaj

×

8

Publications

1K

Citations

8

H-Index

YearCitations

Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria

Mark J. McKeage, Lenushka Maharaj, Susan J. Berners‐Price

Coordination Chemistry Reviews

2002

242

In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake

Jianzhong Liu, Peter Galettis, Alistair Farr,

Journal of Inorganic Biochemistry

2007

179

Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity

Sandra J. Strauss, Lenushka Maharaj, Susan Hoare,

Journal of Clinical Oncology

2006

171

GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death

Matthew Streetly, Lenushka Maharaj, Simon Joel,

Blood

2010

131

P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse

Sunil Iyengar, Andrew Clear, Csaba Bödör,

Blood

2013

126

The Proteasome Inhibitor Bortezomib Acts Independently of p53 and Induces Cell Death via Apoptosis and Mitotic Catastrophe in B-Cell Lymphoma Cell Lines

Sandra J. Strauss, Karen Higginbottom, Simone Jüliger,

Cancer Research

2007

112

Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines

Shireen Kassam, Heidi Goenaga‐Infante, Lenushka Maharaj,

Cancer Chemotherapy and Pharmacology

2011

37

Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).

Sandra J. Strauss, Lenushka Maharaj, Jim Stec,

Blood

2004

19

Page 1